Quest Laboratories Ltd
Founded in June 1998, Quest Laboratories Limited produces a diverse range of pharmaceuticals, including antibiotics, antimalarials, anti-inflammatories, etc.[1]
- Market Cap ₹ 228 Cr.
- Current Price ₹ 139
- High / Low ₹ 159 / 102
- Stock P/E 22.6
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 79.5 %
- ROE 67.2 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 54.3%
- Debtor days have improved from 114 to 88.2 days.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| 30 | 59 | 62 | 83 | |
| 29 | 53 | 54 | 67 | |
| Operating Profit | 1 | 6 | 8 | 16 |
| OPM % | 5% | 11% | 13% | 19% |
| 0 | 0 | 0 | 0 | |
| Interest | 0 | 0 | 1 | 1 |
| Depreciation | 0 | 0 | 1 | 1 |
| Profit before tax | 1 | 6 | 7 | 14 |
| Tax % | 18% | 29% | 28% | 30% |
| 1 | 4 | 5 | 10 | |
| EPS in Rs | 8.45 | |||
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 40% |
| TTM: | 34% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 148% |
| TTM: | 101% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 54% |
| Last Year: | 67% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 12 |
| Reserves | 5 | 9 | 14 | 17 |
| 3 | 3 | 4 | 5 | |
| 9 | 22 | 28 | 26 | |
| Total Liabilities | 18 | 35 | 47 | 59 |
| 6 | 7 | 10 | 10 | |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| 12 | 27 | 37 | 49 | |
| Total Assets | 18 | 35 | 47 | 59 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| 1 | 3 | 4 | 3 | |
| -1 | -2 | -3 | -5 | |
| 0 | -0 | 0 | 2 | |
| Net Cash Flow | -0 | 1 | 1 | 0 |
Ratios
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Debtor Days | 110 | 135 | 118 | |
| Inventory Days | 12 | 9 | 97 | |
| Days Payable | 119 | 140 | 215 | |
| Cash Conversion Cycle | 3 | 4 | 1 | |
| Working Capital Days | 31 | 25 | 40 | |
| ROCE % | 55% | 47% |
Documents
Announcements
-
Updates
10 June 2024 - Quest Laboratories Limited has informed regarding ''Investor update for the year ended 31st March, 2024 & year ended 31st March, 2023'.'.
-
Outcome of Board Meeting
30 May 2024 - Quest Laboratories Limited has informed regarding Outcome of Board Meeting held on May 30, 2024.
-
Financial Result Updates
30 May 2024 - Quest Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2024.
-
Board Meeting Intimation
29 May 2024 - Quest Laboratories Limited has informed about Board Meeting to be held on 30-May-2024 to inter-alia consider and approve the Audited Financial results of the Company …
-
Trading Window
29 May 2024 - Quest Laboratories Limited has informed regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Annual reports
No data available.
Product Profile[1] The company produces ethical drugs, generic drugs, and over-the-counter drugs (OTC). These products are available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids.